Recent News

• 06.12.2025 - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
• 06.12.2025 - Blueprint Medicines Announces Data Reinforcing Sustained Clinical Efficacy and Well-Tolerated Safety Profile of Long-Term AYVAKIT®/AYVAKYT® (avapritinib) Treatment at 2025 EHA and EAACI Congresses
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.11.2025 - Goldman Sachs 46th Annual Global Healthcare Conference
• 06.04.2025 - Blueprint Medicines MCAS Scientific Seminar
• 06.04.2025 - Blueprint Medicines MCAS Scientific Seminar
• 06.02.2025 - Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology
• 06.02.2025 - Sanofi to acquire Blueprint Medicines, expanding portfolio in rare immunological disease and adding early-stage pipeline in immunology

Recent Filings

• 06.05.2025 - 4 Statement of changes in beneficial ownership of securities
• 06.03.2025 - SC TO-C Written communication relating to an issuer or third party
• 06.02.2025 - EX-99.1 EX-99.1
• 06.02.2025 - SC14D9C Written communication relating to third party tender offer
• 06.02.2025 - SC TO-C Written communication relating to an issuer or third party
• 06.02.2025 - SC14D9C Written communication relating to third party tender offer
• 06.02.2025 - SC TO-C Written communication relating to an issuer or third party
• 06.02.2025 - 8-K Current report
• 05.29.2025 - 4 Statement of changes in beneficial ownership of securities
• 05.27.2025 - 144 Report of proposed sale of securities